hrp0097p2-314 | Late Breaking | ESPE2023

Evaluation of the usefulness of antymüllerian hormone and inhibin B as markers of ovarian reserve in girls with hyper- and hypogonadotropic hypogonadism

Latyshev Oleg , Kabolova Kseniya , Okminyan Goar , Kiseleva Elena , Romaykina Daria , Samsonova Lubov

Hypogonadism is represented by a hypo- and hypergonadotropic variant. Antymüllerian hormone (AMH) and inhibin B are used to assess ovarian reserve, but in pediatric practice their role has not been studied. The main interest is to conduct the study of ovarian reserve in hypogonadism among girls.Objective of the Research: To compare the content of inhibin B, AMH and estradiol in girls with hyper- and hypogonadotropic hypogonadism...

hrp0098fc7.1 | GH and IGFs | ESPE2024

Clinical characteristics and response to growth hormone treatment in 27 children and adolescents with pathogenic NPR2 variants

S. Renes Judith , M.J. Reedijk Ardine , M.C. Hendriks Yvonne , Bakker Boudewijn , M. Boot Annemieke , A. van Setten Petra , C.M. van der Kaay Daniëlle , C.S. Hokken-Koelega Anita , Losekoot Monique , A. van Duyvenvoorde Hermine , de Bruin Christiaan

Background: The NPR2 gene plays a critical role in the human growth plate. Pathogenic NPR2 variants can result in varying degrees of short stature. The majority of subjects have no specific clinical findings and are likely classified as idiopathic short stature.Objective: To describe the phenotypic spectrum, analyze genotype-phenotype correlations and assess the response and safety of growth hormone (GH...

hrp0098p2-12 | Adrenals and HPA Axis | ESPE2024

Central adrenal assessment in a group of prepuberal Prader Willi Syndrome patients in a tertiary center

Quarracino Malena , Manuel Lazzati Juan , Eugenia Foncuberta Maria , Guercio Gabriela , Obregon Gabriela , Belgorosky Alicia , Vaiani Elisa

Introduction: Prader Willi Syndrome (PWS) is a genetic disorder caused by the lack of expression of paternally inherited genes in chromosome 15q11-q13 region. Central adrenal insufficiency (CAI) has been described but its prevalence is unknown.Aim: to assess central adrenal function in a group of prepuberal PWS patients suspected of CAI.Methods: PWS patients with confirmed molecula...

hrp0097p2-164 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Precocious puberty: let's talk about the north of Algeria!!

Rouabah Nadira , Rouabah Hamza , Manaa Ardjouna , Bioud Belkacem

La puberté précoce est définie comme le développement des caractéristiques sexuelles avant l'âge de 8 ans chez les filles et de 9,5 ans chez les garçons. L'objectif de notre étude était de calculer la prévalence de la puberté précoce en consultation spécialisée et de décrire le profil clinique, paraclinique, étiologique et de prise en charge ainsi que la qua...

hrp0098p1-267 | Growth and Syndromes 4 | ESPE2024

The clinical burden and healthcare resource utilization among children and adolescents with achondroplasia: an observational cohort study using Optum’s de-identified Clinformatics® Data Mart Database

Abraham Pranav , Miles Gandarvaka , Petruski-Ivleva Natalia , I. Berger Kenneth

Background: Achondroplasia is the most common skeletal dysplasia associated with inhibited growth development and disproportionately short stature; morbidity and complications are apparent at birth and continue throughout life. We assessed the clinical and healthcare resource utilization (HCRU) burden of achondroplasia in US children and adolescents.Methods: This retrospective study assessed children and adolescents (age...

hrp0098p2-54 | Bone, Growth Plate and Mineral Metabolism | ESPE2024

The clinical burden and healthcare resource utilization among children and adolescents with osteogenesis imperfecta: an observational study using Optum’s de-identified Clinformatics® Data Mart Database

Abraham Pranav , Miles Gandarvaka , Petruski-Ivleva Natalia , Hawaldar Kalyani , I. Berger Kenneth

Objectives: Osteogenesis imperfecta (OI) is a skeletal dysplasia affecting 1–2 individuals per 20,000 live births, but the burden of disease in children and adolescents remains unclear. We assessed the clinical and healthcare resource utilization (HCRU) burden of OI in US clinical practice.Methods: This retrospective cohort study included children and adolescents (aged ≤19 years) with OI (≥1 inpatient claim, ...

hrp0098p2-56 | Bone, Growth Plate and Mineral Metabolism | ESPE2024

Real-world effectiveness of vosoritide in children with achondroplasia: Results from 18 months follow-up in France

Cormier-Daire Valerie , Edouard Thomas , Isidor Bertrand , Pimenta Jeanne , Mukherjee Swati , Marcos Valeria , Dee Anne , Rossi Massimiliano , Schaefer Elise , Sigaudy Sabine , Baujat Geneviève

Introduction: Achondroplasia is the most common skeletal dysplasia, caused by a pathogenic FGFR3 variant, leading to impaired endochondral bone growth and multiple medical complications. Vosoritide, a modified recombinant human C-type natriuretic peptide (rhCNP), was first approved by the European Medicines Agency in August 2021 and is now approved for treating genetically-confirmed achondroplasia in patients aged ≥4 months until closure of epiphys...

hrp0098p2-338 | Late Breaking | ESPE2024

Reducing BMI below the obesity threshold in children aged 6 to <12 years treated with once-daily liraglutide 3.0 mg: A secondary analysis of the SCALE Kids study

K. Fox Claudia , Barrientos-Pérez Margarita , M. Bomberg Eric , Dcruz John , Gies Inge , Majlund Harder-Lauridsen Nina , Yazid Jalaludin Muhammad , Sahu Kushal , Weimers Petra , Zueger Thomas , Arslanian Silva

Childhood obesity is associated with present and future complications, including type 2 diabetes and cardiovascular disease. Although lifestyle interventions (i.e. dietary and physical activity counselling) are the cornerstone of therapy, their impact on body mass index (BMI) is limited. The phase 3a SCALE Kids study (NCT04775082) demonstrated superiority of liraglutide 3.0 mg versus placebo, plus lifestyle interventions, for BMI reduction in children with general (i.e. non-mo...

hrp0095p1-459 | Diabetes and Insulin | ESPE2022

Usefulness of glycated albumin level as a glycemic index complementing glycosylated hemoglobin in children and adolescents

Ju Choi Young , Jeong Jang Min , Shin Chungwoo , Bae Ahn Moon , Ho Jung Min , Suh Byung-Kyu

Introduction: Serum glycated albumin (GA) is a glycemic marker reflecting the average serum glucose values for the previous 2 weeks. The purpose of this study was to evaluate the usefulness of serum GA as a glycemic index complementing glycosylated hemoglobin (HbA1c) in children and adolescents.Methods: Fifty-four children and adolescents with diabetes mellitus (DM) and 98 children and adolescents without DM (Non-DM) wer...

hrp0095p1-464 | Fat, Metabolism and Obesity | ESPE2022

Triglyceride glucose index is associated with the severity of ultrasonographic fatty liver indicator in pediatric non-alcoholic steatohepatitis

Gyeol Kim Bit , Seo Yoon Jong , Tae Hwang Il

Background: Triglyceride glucose (TyG) index is known as a reliable insulin resistance surrogate marker to identify non-alcoholic fatty liver disease (NAFLD). Ultrasound fatty liver indicator (US-FLI) is proposed as a non-invasive, semi-quantitative method for predicting hepatitis in children with NAFLD and may reflect the severity of liver histological changes. US-FLI ≥4 has been suggested as a predictive finding for severe NASH. US-FLI correlates signific...